How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    References

    1. Guo RQ, Guo XX, Li YM et al. (2021) Cryoablation, high-intensity focused ultrasound, irreversible electroporation, and vascular-targeted photodynamic therapy for prostate cancer: a systemic review and meta-analysis. International Journal of Clinical Oncology, 26(3): 461–84.

    2. Guenther E, Klein N, Zapf S et al. (2019) Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments. PloS One, 14(4): e0215093.

    3. Blazevski A, Scheltema MJ, Yuen B et al. (2020) Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort. European Urology Oncology, 3(3): 283–290.

    4. Scheltema MJ, Chang JI, Bohm M et al. (2018) Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy. World Journal of Urology, 36(9): 1383–9.

    5. van den Bos W, Scheltema MJ, Siriwardana AR et al. (2018) Focal irreversible electroporation as primary treatment for localised prostate cancer. BJU International, 121(5): 716–24.

    6. Scheltema MJ, Chang JI, van den Bos W et al. (2018) Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments. Diagnostic and Interventional Radiology (Ankara, Turkey), 24(5): 268–75.

    7. Blazevski A, Amin A, Scheltema MJ et al. (2021) Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE). World Journal of Urology, 39(4); 1107-14.